BUKUSIEA, COHEN CR, NGUTI R, MUNGAI JN, WAIYAKI PW, KARANJA JG, HOLMES KK Evaluation of "Femexan" Rapid Test for the Diagnosis of Bacterial Vaginosis in Kenya. Journal of Obstetrics and Gynaecology of Eastern and Central Africa. 17: 1, 57-61, February 200

Citation:
G PROFKARANJAJOSEPH, OTIENO DRODAWAFRANCISXAVIER. "BUKUSIEA, COHEN CR, NGUTI R, MUNGAI JN, WAIYAKI PW, KARANJA JG, HOLMES KK Evaluation of "Femexan" Rapid Test for the Diagnosis of Bacterial Vaginosis in Kenya. Journal of Obstetrics and Gynaecology of Eastern and Central Africa. 17: 1, 57-61, February 200.". In: Journal of Obstetrics and Gynaecology of Eastern and Central Africa. 17: 1, 57-61, February 2004. Korean Society of Crop Science and Springer; 2004.

Abstract:

OBJECTIVE: We compared 12-month continuation rates, menstrual bleeding patterns and other aspects of acceptability between users of Cyclofem and users of Depo-Provera. METHODS: The life-table method was used to calculate quarterly continuation rates. In all, 360 Kenyan women were randomly assigned to one of the two contraceptives. User-satisfaction questionnaires were administered at 6 and 12 months or at discontinuation, whichever occurred first. RESULTS: The 1-year continuation rate was 75.4% for Depo-Provera users versus 56.5% for Cyclofem users (p<.001). Main reasons for discontinuation included difficulty making clinic visits (45.1% for Cyclofem vs. 40% for Depo-Provera), menstrual changes (14.1% vs. 12.5%) and nonmenstrual problems (15.5% vs. 12.5%). None of the Depo-Provera users and 8.5% of the Cyclofem users claimed frequency of visits as the main reason for discontinuation. In all, 70.6% of the Depo-Provera users were amenorrheic after 12 months, as were 20.8% of the Cyclofem users. CONCLUSIONS: The 1-year continuation rate was higher for Depo-Provera than for Cyclofem. There was no important difference in discontinuation rates because of menstrual problems; the difference mainly reflected the frequency of visits required.

Notes:

n/a

Website

UoN Websites Search